Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Merck : Janssen to Develop Automated Diagnostic Tool for Neglected Tropical Diseases

share with twitter share with LinkedIn share with facebook
07/02/2020 | 05:46am EDT

By Giulia Petroni

Merck KGaA said Thursday that it would partner with Janssen Pharmaceutica NV to develop an artificial intelligence-based diagnostic tool for the detection of neglected tropical diseases.

The German pharmaceutical and chemicals company said the prototype that is being tested consists of an automated microscope with AI and data visualisation tool. It enables the counting of parasite eggs that develop into parasitic worms of either schistosomiasis or soil-transmitted helminthiasis.

"This automated counting process is aimed at being both faster and more reliable than the current survey method, in which a lab technician counts the eggs in each sample manually," it said.

The prototype testing is set to continue throughout the year and pass to the clinical utility testing phase in 2021 through 2023, according to Merck KGaA.

Janssen Pharmaceutica is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

 

Write to Giulia Petroni at giulia.petroni@wsj.com

 

Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON -0.38% 148.03 Delayed Quote.1.87%
MERCK KGAA 1.38% 114 Delayed Quote.6.74%
share with twitter share with LinkedIn share with facebook
Latest news on MERCK KGAA
08/10MERCK KGAA : Gets a Buy rating from DZ Bank
MD
08/07European Companies Continue Reinstating Guidance Amid Coronavirus Uncertainty..
DJ
08/07MERCK KGAA : Receives a Buy rating from Kepler Cheuvreux
MD
08/07MERCK KGAA : Independant Research reiterates its Buy rating
MD
08/07MERCK KGAA : UBS reiterates its Neutral rating
MD
08/07MERCK KGAA : Bernstein gives a Neutral rating
MD
08/07MERCK KGAA : Barclays reiterates its Sell rating
MD
08/07MERCK KGAA : Goldman Sachs reiterates its Sell rating
MD
08/07MERCK KGAA : Credit Suisse remains its Buy rating
MD
08/06MERCK KGAA : NorldLB sticks Neutral
MD
More news
Financials
Sales 2020 17 283 M 20 390 M 20 390 M
Net income 2020 1 706 M 2 013 M 2 013 M
Net Debt 2020 10 788 M 12 727 M 12 727 M
P/E ratio 2020 28,0x
Yield 2020 1,19%
Capitalization 48 891 M 57 512 M 57 679 M
EV / Sales 2020 3,45x
EV / Sales 2021 3,18x
Nbr of Employees 57 523
Free-Float 29,7%
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 115,47 €
Last Close Price 112,45 €
Spread / Highest target 33,4%
Spread / Average Target 2,69%
Spread / Lowest Target -18,2%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Christian Raabe Independent Member-Supervisory Board
Edeltraud Glänzer Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA6.74%57 512
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD82.59%17 386
KYOWA KIRIN CO., LTD.4.97%13 714
BETTA PHARMACEUTICALS CO., LTD.119.70%8 336
JAZZ PHARMACEUTICALS PLC-15.36%7 007
YUHAN CORPORATION41.23%3 515